BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

717 related articles for article (PubMed ID: 33938021)

  • 1. Genomewide Association Studies of LRRK2 Modifiers of Parkinson's Disease.
    Lai D; Alipanahi B; Fontanillas P; Schwantes-An TH; Aasly J; Alcalay RN; Beecham GW; Berg D; Bressman S; Brice A; Brockman K; Clark L; Cookson M; Das S; Van Deerlin V; Follett J; Farrer MJ; Trinh J; Gasser T; Goldwurm S; Gustavsson E; Klein C; Lang AE; Langston JW; Latourelle J; Lynch T; Marder K; Marras C; Martin ER; McLean CY; Mejia-Santana H; Molho E; Myers RH; Nuytemans K; Ozelius L; Payami H; Raymond D; Rogaeva E; Rogers MP; Ross OA; Samii A; Saunders-Pullman R; Schüle B; Schulte C; Scott WK; Tanner C; Tolosa E; Tomkins JE; Vilas D; Trojanowski JQ; ; Uitti R; Vance JM; Visanji NP; Wszolek ZK; Zabetian CP; Mirelman A; Giladi N; Orr Urtreger A; Cannon P; Fiske B; Foroud T
    Ann Neurol; 2021 Jul; 90(1):76-88. PubMed ID: 33938021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNM3 and genetic modifiers of age of onset in LRRK2 Gly2019Ser parkinsonism: a genome-wide linkage and association study.
    Trinh J; Gustavsson EK; Vilariño-Güell C; Bortnick S; Latourelle J; McKenzie MB; Tu CS; Nosova E; Khinda J; Milnerwood A; Lesage S; Brice A; Tazir M; Aasly JO; Parkkinen L; Haytural H; Foroud T; Myers RH; Sassi SB; Hentati E; Nabli F; Farhat E; Amouri R; Hentati F; Farrer MJ
    Lancet Neurol; 2016 Nov; 15(12):1248-1256. PubMed ID: 27692902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomewide linkage study of modifiers of LRRK2-related Parkinson's disease.
    Latourelle JC; Hendricks AE; Pankratz N; Wilk JB; Halter C; Nichols WC; Gusella JF; Destefano AL; Myers RH; Foroud T;
    Mov Disord; 2011 Sep; 26(11):2039-44. PubMed ID: 21661047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic analysis and natural history of Parkinson's disease due to the LRRK2 G2019S variant.
    Kmiecik MJ; Micheletti S; Coker D; Heilbron K; Shi J; Stagaman K; Filshtein Sonmez T; Fontanillas P; Shringarpure S; Wetzel M; Rowbotham HM; Cannon P; Shelton JF; Hinds DA; Tung JY; ; Holmes MV; Aslibekyan S; Norcliffe-Kaufmann L
    Brain; 2024 Jun; 147(6):1996-2008. PubMed ID: 38804604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study.
    Healy DG; Falchi M; O'Sullivan SS; Bonifati V; Durr A; Bressman S; Brice A; Aasly J; Zabetian CP; Goldwurm S; Ferreira JJ; Tolosa E; Kay DM; Klein C; Williams DR; Marras C; Lang AE; Wszolek ZK; Berciano J; Schapira AH; Lynch T; Bhatia KP; Gasser T; Lees AJ; Wood NW;
    Lancet Neurol; 2008 Jul; 7(7):583-90. PubMed ID: 18539534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leucine-Rich Repeat Kinase (LRRK2) Genetics and Parkinson's Disease.
    Monfrini E; Di Fonzo A
    Adv Neurobiol; 2017; 14():3-30. PubMed ID: 28353276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Penetrance estimate of LRRK2 p.G2019S mutation in individuals of non-Ashkenazi Jewish ancestry.
    Lee AJ; Wang Y; Alcalay RN; Mejia-Santana H; Saunders-Pullman R; Bressman S; Corvol JC; Brice A; Lesage S; Mangone G; Tolosa E; Pont-Sunyer C; Vilas D; Schüle B; Kausar F; Foroud T; Berg D; Brockmann K; Goldwurm S; Siri C; Asselta R; Ruiz-Martinez J; Mondragón E; Marras C; Ghate T; Giladi N; Mirelman A; Marder K;
    Mov Disord; 2017 Oct; 32(10):1432-1438. PubMed ID: 28639421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RAB32 Ser71Arg in autosomal dominant Parkinson's disease: linkage, association, and functional analyses.
    Gustavsson EK; Follett J; Trinh J; Barodia SK; Real R; Liu Z; Grant-Peters M; Fox JD; Appel-Cresswell S; Stoessl AJ; Rajput A; Rajput AH; Auer R; Tilney R; Sturm M; Haack TB; Lesage S; Tesson C; Brice A; Vilariño-Güell C; Ryten M; Goldberg MS; West AB; Hu MT; Morris HR; Sharma M; Gan-Or Z; Samanci B; Lis P; Periñan MT; Amouri R; Ben Sassi S; Hentati F; ; Tonelli F; Alessi DR; Farrer MJ
    Lancet Neurol; 2024 Jun; 23(6):603-614. PubMed ID: 38614108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of DNM3 and VAMP4 as genetic modifiers of LRRK2 Parkinson's disease.
    Brown EE; Blauwendraat C; Trinh J; Rizig M; Nalls MA; Leveille E; Ruskey JA; Jonvik H; Tan MMX; Bandres-Ciga S; Hassin-Baer S; Brockmann K; Infante J; Tolosa E; Ezquerra M; Ben Romdhan S; Benmahdjoub M; Arezki M; Mhiri C; Hardy J; Singleton AB; Alcalay RN; Gasser T; Grosset DG; Williams NM; Pittman A; Gan-Or Z; Fernandez-Santiago R; Brice A; Lesage S; Farrer M; Wood N; Morris HR;
    Neurobiol Aging; 2021 Jan; 97():148.e17-148.e24. PubMed ID: 32873436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LRRK2 haplotype-sharing analysis in Parkinson's disease reveals a novel p.S1761R mutation.
    Lorenzo-Betancor O; Samaranch L; Ezquerra M; Tolosa E; Lorenzo E; Irigoyen J; Gaig C; Pastor MA; Soto-Ortolaza AI; Ross OA; Rodríguez-Oroz MC; Valldeoriola F; Martí MJ; Luquin MR; Perez-Tur J; Burguera JA; Obeso JA; Pastor P
    Mov Disord; 2012 Jan; 27(1):146-51. PubMed ID: 22038903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Occupational Pesticide Exposure in Parkinson's Disease Related to GBA and LRRK2 Variants.
    Brown EG; Goldman SM; Coffey CS; Siderowf A; Simuni T; Meng C; Brumm MC; Caspell-Garcia C; Marek K; Tanner CM;
    J Parkinsons Dis; 2024; 14(4):737-746. PubMed ID: 38820021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resequencing analysis of five Mendelian genes and the top genes from genome-wide association studies in Parkinson's Disease.
    Benitez BA; Davis AA; Jin SC; Ibanez L; Ortega-Cubero S; Pastor P; Choi J; Cooper B; Perlmutter JS; Cruchaga C
    Mol Neurodegener; 2016 Apr; 11():29. PubMed ID: 27094865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Penetrance of Parkinson's Disease in LRRK2 p.G2019S Carriers Is Modified by a Polygenic Risk Score.
    Iwaki H; Blauwendraat C; Makarious MB; Bandrés-Ciga S; Leonard HL; Gibbs JR; Hernandez DG; Scholz SW; Faghri F; ; Nalls MA; Singleton AB
    Mov Disord; 2020 May; 35(5):774-780. PubMed ID: 31958187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. α-synuclein (SNCA) but not dynamin 3 (DNM3) influences age at onset of leucine-rich repeat kinase 2 (LRRK2) Parkinson's disease in Spain.
    Fernández-Santiago R; Garrido A; Infante J; González-Aramburu I; Sierra M; Fernández M; Valldeoriola F; Muñoz E; Compta Y; Martí MJ; Ríos J; Tolosa E; Ezquerra M;
    Mov Disord; 2018 Apr; 33(4):637-641. PubMed ID: 29473656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carriers of both GBA and LRRK2 mutations, compared to carriers of either, in Parkinson's disease: Risk estimates and genotype-phenotype correlations.
    Yahalom G; Greenbaum L; Israeli-Korn S; Fay-Karmon T; Livneh V; Ruskey JA; Roncière L; Alam A; Gan-Or Z; Hassin-Baer S
    Parkinsonism Relat Disord; 2019 May; 62():179-184. PubMed ID: 30573413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive LRRK2 and GBA screening in Portuguese patients with Parkinson's disease: identification of a new family with the LRRK2 p.Arg1441His mutation and novel missense variants.
    Zhang L; Quadri M; Guedes LC; Coelho M; Valadas A; Mestre T; Lobo PP; Rosa MM; Simons E; Oostra BA; Ferreira JJ; Bonifati V
    Parkinsonism Relat Disord; 2013 Oct; 19(10):897-900. PubMed ID: 23726462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LRRK2 Gly2019Ser penetrance in Arab-Berber patients from Tunisia: a case-control genetic study.
    Hulihan MM; Ishihara-Paul L; Kachergus J; Warren L; Amouri R; Elango R; Prinjha RK; Upmanyu R; Kefi M; Zouari M; Sassi SB; Yahmed SB; El Euch-Fayeche G; Matthews PM; Middleton LT; Gibson RA; Hentati F; Farrer MJ
    Lancet Neurol; 2008 Jul; 7(7):591-4. PubMed ID: 18539535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonsteroidal Anti-inflammatory Use and LRRK2 Parkinson's Disease Penetrance.
    San Luciano M; Tanner CM; Meng C; Marras C; Goldman SM; Lang AE; Tolosa E; Schüle B; Langston JW; Brice A; Corvol JC; Goldwurm S; Klein C; Brockman S; Berg D; Brockmann K; Ferreira JJ; Tazir M; Mellick GD; Sue CM; Hasegawa K; Tan EK; Bressman S; Saunders-Pullman R;
    Mov Disord; 2020 Oct; 35(10):1755-1764. PubMed ID: 32662532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genomewide association study of Parkinson's disease clinical biomarkers in 12 longitudinal patients' cohorts.
    Iwaki H; Blauwendraat C; Leonard HL; Kim JJ; Liu G; Maple-Grødem J; Corvol JC; Pihlstrøm L; van Nimwegen M; Hutten SJ; Nguyen KH; Rick J; Eberly S; Faghri F; Auinger P; Scott KM; Wijeyekoon R; Van Deerlin VM; Hernandez DG; Gibbs JR; ; Chitrala KN; Day-Williams AG; Brice A; Alves G; Noyce AJ; Tysnes OB; Evans JR; Breen DP; Estrada K; Wegel CE; Danjou F; Simon DK; Andreassen O; Ravina B; Toft M; Heutink P; Bloem BR; Weintraub D; Barker RA; Williams-Gray CH; van de Warrenburg BP; Van Hilten JJ; Scherzer CR; Singleton AB; Nalls MA
    Mov Disord; 2019 Dec; 34(12):1839-1850. PubMed ID: 31505070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LRRK2 in Parkinson's disease - drawing the curtain of penetrance: a commentary.
    Krüger R
    BMC Med; 2008 Nov; 6():33. PubMed ID: 18986509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.